Redeye remains positive to Strax after a solid Q2-beat, with topline growth of 27% y/y. We had expected a rather tough Q2. Instead, the agile company profile paid off, as the newly launched health & wellness segment sold for EUR 13.3m already in its first quarter. The strong performance will justify an increased base case valuation.